Mycophenolate mofetil: effects on clinical transplantation
Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of gua...
Gespeichert in:
| Veröffentlicht in: | BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy biopharmaceuticals, and gene therapy, 1998-11, Vol.10 (5), p.373-384 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 384 |
|---|---|
| container_issue | 5 |
| container_start_page | 373 |
| container_title | BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy |
| container_volume | 10 |
| creator | Holt, C D Sievers, T M Ghobrial, R M Rossi, S J Goss, J A McDiarmid, S V |
| description | Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combination with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory rejection in renal, heart and liver transplant recipients. |
| doi_str_mv | 10.2165/00063030-199810050-00004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734025543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734025543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c288t-6032b4eef4a91a65e334bdccb3ae7283c4f58ccb098a9228d4eeaf1a4b4cea043</originalsourceid><addsrcrecordid>eNp9kD1PwzAQhj2AaCn8BZQJpsD5I4ndDVV8SUUsMFuOexZBSRxiZ-i_x7QFNqbTnZ737vQQklG4ZrQsbgCg5MAhp0pJClBAnkYgjsic0ornUoKYkdMQPnakqk7IjEpgUIKak-Xz1vrhHXvfmohZ5x3Gpl1m6BzaGDLfZ7Zt-saaNouj6cPQmj6a2Pj-jBw70wY8P9QFebu_e1095uuXh6fV7Tq3TMqYl8BZLRCdMIqaskDORb2xtuYGKya5Fa6QqQUljWJMbhJrHDWiFhYNCL4gV_u9w-g_JwxRd02w2KZH0E9BV1wAKwrBE3n5L0kVr6qSswTKPWhHH8KITg9j05lxqynob6v6x6r-tap3VlP04nBjqjvc_AUPSvkXKLV1AQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19377632</pqid></control><display><type>article</type><title>Mycophenolate mofetil: effects on clinical transplantation</title><source>SpringerLink Journals</source><creator>Holt, C D ; Sievers, T M ; Ghobrial, R M ; Rossi, S J ; Goss, J A ; McDiarmid, S V</creator><creatorcontrib>Holt, C D ; Sievers, T M ; Ghobrial, R M ; Rossi, S J ; Goss, J A ; McDiarmid, S V</creatorcontrib><description>Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combination with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory rejection in renal, heart and liver transplant recipients.</description><identifier>ISSN: 1173-8804</identifier><identifier>DOI: 10.2165/00063030-199810050-00004</identifier><identifier>PMID: 18020609</identifier><language>eng</language><publisher>New Zealand</publisher><ispartof>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 1998-11, Vol.10 (5), p.373-384</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18020609$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Holt, C D</creatorcontrib><creatorcontrib>Sievers, T M</creatorcontrib><creatorcontrib>Ghobrial, R M</creatorcontrib><creatorcontrib>Rossi, S J</creatorcontrib><creatorcontrib>Goss, J A</creatorcontrib><creatorcontrib>McDiarmid, S V</creatorcontrib><title>Mycophenolate mofetil: effects on clinical transplantation</title><title>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy</title><addtitle>BioDrugs</addtitle><description>Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combination with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory rejection in renal, heart and liver transplant recipients.</description><issn>1173-8804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><recordid>eNp9kD1PwzAQhj2AaCn8BZQJpsD5I4ndDVV8SUUsMFuOexZBSRxiZ-i_x7QFNqbTnZ737vQQklG4ZrQsbgCg5MAhp0pJClBAnkYgjsic0ornUoKYkdMQPnakqk7IjEpgUIKak-Xz1vrhHXvfmohZ5x3Gpl1m6BzaGDLfZ7Zt-saaNouj6cPQmj6a2Pj-jBw70wY8P9QFebu_e1095uuXh6fV7Tq3TMqYl8BZLRCdMIqaskDORb2xtuYGKya5Fa6QqQUljWJMbhJrHDWiFhYNCL4gV_u9w-g_JwxRd02w2KZH0E9BV1wAKwrBE3n5L0kVr6qSswTKPWhHH8KITg9j05lxqynob6v6x6r-tap3VlP04nBjqjvc_AUPSvkXKLV1AQ</recordid><startdate>19981101</startdate><enddate>19981101</enddate><creator>Holt, C D</creator><creator>Sievers, T M</creator><creator>Ghobrial, R M</creator><creator>Rossi, S J</creator><creator>Goss, J A</creator><creator>McDiarmid, S V</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19981101</creationdate><title>Mycophenolate mofetil: effects on clinical transplantation</title><author>Holt, C D ; Sievers, T M ; Ghobrial, R M ; Rossi, S J ; Goss, J A ; McDiarmid, S V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c288t-6032b4eef4a91a65e334bdccb3ae7283c4f58ccb098a9228d4eeaf1a4b4cea043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Holt, C D</creatorcontrib><creatorcontrib>Sievers, T M</creatorcontrib><creatorcontrib>Ghobrial, R M</creatorcontrib><creatorcontrib>Rossi, S J</creatorcontrib><creatorcontrib>Goss, J A</creatorcontrib><creatorcontrib>McDiarmid, S V</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Holt, C D</au><au>Sievers, T M</au><au>Ghobrial, R M</au><au>Rossi, S J</au><au>Goss, J A</au><au>McDiarmid, S V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mycophenolate mofetil: effects on clinical transplantation</atitle><jtitle>BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy</jtitle><addtitle>BioDrugs</addtitle><date>1998-11-01</date><risdate>1998</risdate><volume>10</volume><issue>5</issue><spage>373</spage><epage>384</epage><pages>373-384</pages><issn>1173-8804</issn><abstract>Mycophenolate mofetil (MMF) is the morpholinoethylester prodrug of mycophenolic acid, an agent which inhibits the proliferation of B and T lymphocytes through the noncompetitive, reversible inhibition of inosine monophosphate dehydrogenase, itself a key enzyme in the de novo synthetic pathway of guanosine nucleotides. Currently, MMF is approved for the prevention of acute renal allograft rejection when used in combination with cyclosporin and corticosteroids. Several studies have also demonstrated that this drug is useful in the treatment of refractory rejection in renal, heart and liver transplant recipients.</abstract><cop>New Zealand</cop><pmid>18020609</pmid><doi>10.2165/00063030-199810050-00004</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1173-8804 |
| ispartof | BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 1998-11, Vol.10 (5), p.373-384 |
| issn | 1173-8804 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_734025543 |
| source | SpringerLink Journals |
| title | Mycophenolate mofetil: effects on clinical transplantation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T11%3A30%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mycophenolate%20mofetil:%20effects%20on%20clinical%20transplantation&rft.jtitle=BioDrugs%20:%20clinical%20immunotherapeutics,%20biopharmaceuticals,%20and%20gene%20therapy&rft.au=Holt,%20C%20D&rft.date=1998-11-01&rft.volume=10&rft.issue=5&rft.spage=373&rft.epage=384&rft.pages=373-384&rft.issn=1173-8804&rft_id=info:doi/10.2165/00063030-199810050-00004&rft_dat=%3Cproquest_cross%3E734025543%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19377632&rft_id=info:pmid/18020609&rfr_iscdi=true |